Cost-Utility Analysis of Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms

Overview

Journal Cardiovasc Intervent Radiol

Specialty Cardiology & Vascular Diseases

Date 2023 May 4

PMID 37142802

Authors

Ferran Capdevila

Inigo Insausti

Ramon San Miguel

Eduardo Sanchez-Iriso

Manuel Montesino

Affiliations

Soon will be listed here.

Abstract

Purpose: To perform a post hoc cost-utility analysis of a randomized controlled clinical trial comparing prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Materials And Methods: We conducted a cost-utility analysis over a 5-year period to compare PAE versus TURP from a Spanish National Health System perspective. Data were collected from a randomized clinical trial performed at a single institution. Effectiveness was measured as quality-adjusted life years (QALYs), and an incremental cost-effectiveness ratio (ICER) was derived from the cost and QALY values associated with these treatments. Further sensitivity analysis was performed to account for the impact of reintervention on the cost-effectiveness of both procedures.

Results: At the 1-year follow-up, PAE resulted in mean cost per patient of €2904.68 and outcome of 0.975 QALYs per treatment. In comparison, TURP had cost €3846.72 per patient and its outcome was 0.953 QALYs per treatment. At 5 years, the cost for PAE and TURP were €4117.13 and €4297.58, and the mean QALY outcome was 4.572 and 4.487, respectively. Analysis revealed an ICER of €2121.15 saved per QALY gained when comparing PAE to TURP at long-term follow-up. Reintervention rate for PAE and TURP was 12% and 0%, respectively.

Conclusions: Compared to TURP, in short term, PAE could be considered a cost-effective strategy within the Spanish healthcare system for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. However, in long term, the superiority is less apparent due to higher reintervention rates.

Citing Articles

Prostatic Artery Embolization in Elderly Comorbid Patients with Benign Prostatic Hyperplasia: Safety, Efficacy, and Predictive Factors of Clinical Failure.

Zorzi F, Rossin G, Digregorio M, Lavecchia S, Piasentin A, Traunero F J Pers Med. 2025; 15(1).

PMID: 39852215 PMC: 11767102. DOI: 10.3390/jpm15010023.

A real-world evidence study of interhospital variability in the surgical treatment of patients with benign prostatic hyperplasia: the REVALURO study.

Ivan P, Alberto B, Lluis P, Maurizio D, Jose Luis G, Francisco Javier V Int Urol Nephrol. 2024; 57(3):775-784.

PMID: 39470938 PMC: 11821794. DOI: 10.1007/s11255-024-04239-7.

References

Lim K . Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017; 4(3):148-151. PMC: 5717991. DOI: 10.1016/j.ajur.2017.06.004. View

Insausti I, de Ocariz A, Galbete A, Capdevila F, Solchaga S, Giral P . Randomized Comparison of Prostatic Artery Embolization versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia. J Vasc Interv Radiol. 2020; 31(6):882-890. DOI: 10.1016/j.jvir.2019.12.810. View

Abt D, Mullhaupt G, Hechelhammer L, Markart S, Gusewell S, Schmid H . Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. Eur Urol. 2021; 80(1):34-42. DOI: 10.1016/j.eururo.2021.02.008. View

Gao Y, Huang Y, Zhang R, Yang Y, Zhang Q, Hou M . Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate--a prospective, randomized, and controlled clinical trial. Radiology. 2014; 270(3):920-8. DOI: 10.1148/radiol.13122803. View

Carnevale F, Iscaife A, Yoshinaga E, Moreira A, Antunes A, Srougi M . Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis. Cardiovasc Intervent Radiol. 2015; 39(1):44-52. DOI: 10.1007/s00270-015-1202-4. View

Pisco J, Bilhim T, Pinheiro L, Fernandes L, Pereira J, Costa N . Medium- and Long-Term Outcome of Prostate Artery Embolization for Patients with Benign Prostatic Hyperplasia: Results in 630 Patients. J Vasc Interv Radiol. 2016; 27(8):1115-22. DOI: 10.1016/j.jvir.2016.04.001. View

Ray A, Powell J, Speakman M, Longford N, Dasgupta R, Bryant T . Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. 2018; 122(2):270-282. DOI: 10.1111/bju.14249. View

Uflacker A, Haskal Z, Bilhim T, Patrie J, Huber T, Pisco J . Meta-Analysis of Prostatic Artery Embolization for Benign Prostatic Hyperplasia. J Vasc Interv Radiol. 2016; 27(11):1686-1697.e8. DOI: 10.1016/j.jvir.2016.08.004. View

Foster H, Barry M, Dahm P, Gandhi M, Kaplan S, Kohler T . Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol. 2018; 200(3):612-619. DOI: 10.1016/j.juro.2018.05.048. View

10.

Rink J, Froelich M, McWilliams J, Gratzke C, Huber T, Gresser E . Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms: A Markov Model-Based Cost-Effectiveness Analysis. J Am Coll Radiol. 2022; 19(6):733-743. DOI: 10.1016/j.jacr.2022.02.040. View

11.

Wu X, Zhou A, Heller M, Kohlbrenner R . Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis. J Vasc Interv Radiol. 2022; 33(12):1605-1615. DOI: 10.1016/j.jvir.2022.08.006. View

12.

Capdevila F, Insausti I, Galbete A, Sanchez-Iriso E, Montesino M . Prostatic Artery Embolization Versus Transurethral Resection of the Prostate: A Post Hoc Cost Analysis of a Randomized Controlled Clinical Trial. Cardiovasc Intervent Radiol. 2021; 44(11):1771-1777. PMC: 8549945. DOI: 10.1007/s00270-021-02920-3. View

13.

Vallejo-Torres L, Garcia-Lorenzo B, Serrano-Aguilar P . Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2017; 27(4):746-761. DOI: 10.1002/hec.3633. View

14.

Kok E, Mcdonnell J, Stolk E, Stoevelaar H, Busschbach J . The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations. Eur Urol. 2002; 42(5):491-7. DOI: 10.1016/s0302-2838(02)00403-7. View

15.

Bermingham S, Hodgkinson S, Wright S, Hayter E, Spinks J, Pellowe C . Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis. BMJ. 2013; 346:e8639. PMC: 3541473. DOI: 10.1136/bmj.e8639. View

16.

Mullhaupt G, Hechelhammer L, Engeler D, Gusewell S, Betschart P, Zumstein V . In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. BJU Int. 2018; 123(6):1055-1060. PMC: 6850481. DOI: 10.1111/bju.14660. View

17.

Bagla S, Smirniotopoulos J, Orlando J, Piechowiak R . Cost Analysis of Prostate Artery Embolization (PAE) and Transurethral Resection of the Prostate (TURP) in the Treatment of Benign Prostatic Hyperplasia. Cardiovasc Intervent Radiol. 2017; 40(11):1694-1697. DOI: 10.1007/s00270-017-1700-7. View

18.

Bilhim T, Vasco Costa N, Torres D, Pinheiro L, Spaepen E . Long-Term Outcome of Prostatic Artery Embolization for Patients with Benign Prostatic Hyperplasia: Single-Centre Retrospective Study in 1072 Patients Over a 10-Year Period. Cardiovasc Intervent Radiol. 2022; 45(9):1324-1336. DOI: 10.1007/s00270-022-03199-8. View

19.

Gilfrich C, May M, Fahlenbrach C, Gunster C, Jeschke E, Popken G . Surgical Reintervention Rates after Invasive Treatment for Lower Urinary Tract Symptoms due to Benign Prostatic Syndrome: A Comparative Study of More than 43,000 Patients with Long-Term Followup. J Urol. 2020; 205(3):855-863. DOI: 10.1097/JU.0000000000001463. View

20.

Malde S, Umbach R, Wheeler J, Lytvyn L, Cornu J, Gacci M . A Systematic Review of Patients' Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms. Eur Urol. 2021; 79(6):796-809. DOI: 10.1016/j.eururo.2020.12.019. View